NATURAL CAPSULES LTD.

Natural Capsules Ltd's material unlisted subsidiary, Natural Biogenex Private Limited, has approved a Rights Issue. The issue involves 11,16,766 equity shares of Rs. 10 each, offered at par, for a total aggregate amount of Rs. 1,11,67,660 (approximately ₹1.11 Crore). This corporate action aims to raise capital for the subsidiary.

Natural Biogenex Private Limited, a material unlisted subsidiary of Natural Capsules Ltd, has approved the allotment of 1,11,202 equity shares of Rs. 10 each for cash at par. This allotment, aggregating to Rs. 11,12,020, follows the right issue duly approved in a previous board meeting on May 27, 2026. The board meeting where this allotment was approved was held on July 10, 2026. This action is in compliance with Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Natural Capsules Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure will be effective from July 01, 2026, and will continue until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The decision is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The exact date for the Board Meeting to declare these financial results will be communicated separately. This measure is standard practice to prevent insider trading during sensitive financial reporting periods.

Natural Capsules Ltd has corrected a typographical error in its May 27, 2026, intimation regarding the Rights Issue of its material unlisted subsidiary, Natural Biogenex Private Limited. The total number of equity shares offered in the approved Rights Issue is revised to 11,11,205 Equity Shares of ₹10 each, with total gross proceeds corrected to ₹1,11,12,050. All other details remain unchanged.

Natural Capsules Limited announced its audited financial results for Q4 and the full year ended March 31, 2026. For Q4 FY26, the company reported a revenue of ₹58.45 Cr and a PAT of (₹4.98 Cr). For the full year FY26, revenue stood at ₹187.20 Cr with a PAT of (₹24.66 Cr). Mr. Sunil Mundra, Executive Director, highlighted Q4 as a strong operational quarter, driven by successful dispatch of goods deferred due to a prior plant shutdown. The incremental HPMC line for double-zero capsules is ready, with revenue expected from H2 FY27. Commercial sales for the API business commenced in Q4 FY26. The subsidiary, Natural Biogenex Private Limited, partnered with Fermbox Bio Private Limited to enhance fermentation-based CDMO capabilities and create new revenue streams. The company aims for optimal capacity utilization, improved operational efficiency in capsules, and scaling the API business in FY27.

Natural Capsules Ltd's material subsidiary, Natural Biogenex Private Limited, approved a rights issue of 11,11,200 equity shares at ₹10 each, aggregating to ₹1,11,12,000 in its board meeting held on May 27, 2026. The rights issue is for cash at par.

Natural Capsules Ltd's board approved the audited standalone and consolidated financial results for FY26. Mr. Shri Laxminarayana Moondra was re-appointed as Whole Time Director for 3 years, subject to shareholder approval. M/s. Mallya & Mallya were appointed as Internal Auditor for FY27. Mr. Akshay Dutta was appointed as Company Secretary & Compliance Officer. 25,000 equity shares were allotted under ESOP 2025, increasing the paid-up share capital to ₹10,41,11,540.

Natural Capsules Ltd. approved audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the re-appointment of Mr. Shri Laxminarayana Moondra as Whole Time Director for 3 years, revised his remuneration, appointed M/s. Mallya & Mallya as Internal Auditor for FY 2026-27, and appointed Mr. Akshay Dutta as Company Secretary & Compliance Officer. Additionally, the NRC approved the allotment of 25,000 equity shares against ESOPs, increasing the paid-up share capital to ₹10,41,11,540.

Natural Capsules Ltd has announced a Board of Directors meeting scheduled for May 27, 2026, to consider and approve the audited standalone and consolidated financial statements for the quarter/year ended March 31, 2026. The trading window for dealing in the company's equity shares has been closed for designated persons and their immediate relatives from April 1, 2026, until 48 hours after the declaration of the financial results.

Natural Capsules Ltd. is participating in the "Second 100 Days Campaign - Saksham Niveshak" from April 1 to July 9, 2026. This initiative, requested by the Investor Education and Protection Fund Authority (IEPFA), aims to help shareholders claim unpaid/unclaimed dividends and update their KYC details before these funds are transferred to the IEPF. Shareholders can contact the company's Registrar and Transfer Agent (RTA), Cameo Corporate Services Limited, or the company directly via email for assistance. The campaign also encourages updating contact details, bank accounts, nominations, and specimen signatures, especially for physical share holders using specific forms. Details of unclaimed dividends from FY2018 to FY2024 are available on the company's website.